AdamL.BoxerMDPhD

Neurology • San Francisco, CA

Endowed Professor in Memory and Aging, University of California, San Francisco

Join to view full profile

Dr. Boxer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boxer's full profile

Already have an account?

Office
675 Nelson Rising Lane
Suite 190
San Francisco, CA 94143
Phone+1 415-353-2057

Fax+1 415-353-8292

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Neurology, 1999 - 2002
California Pacific Medical CenterInternship, Internal Medicine, 1998 - 1999
New York University School of MedicineClass of 1998

Certifications & Licensure

CA State Medical License 1999 - 2025
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Start of enrollment: 2007 Oct 01
Completed
Phase 4
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Start of enrollment: 2010 Jan 01
Completed
Phase 1
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
Recruiting
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 Start of enrollment: 2012 Dec 01
Recruiting
Phase 2, Phase 3
4 Repeat Tauopathy Neuroimaging Initiative Start of enrollment: 2014 Jan 01
Active, not recruiting
Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations Start of enrollment: 2013 Mar 01
Completed
Phase 1
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease Start of enrollment: 2013 Nov 01
Completed
Phase 1
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Completed
Phase 3
Safety Study of TPI-287 to Treat CBS and PSP Start of enrollment: 2014 May 01
Completed
Phase 1
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Start of enrollment: 2015 Apr 01
Completed
Phase 1
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Start of enrollment: 2015 Jul 01
Completed
Phase 1
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 Start of enrollment: 2016 Feb 22
Terminated
Phase 1
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2 Start of enrollment: 2016 Jan 01
Active, not recruiting
Intranasal Oxytocin for Frontotemporal Dementia Start of enrollment: 2018 Jan 31
Active, not recruiting
Phase 2
Salsalate in Patients Mild to Moderate Alzheimer's Disease Start of enrollment: 2017 Jul 21
Active, not recruiting
Phase 1
BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES Start of enrollment: 2018 Sep 12
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Correction to: Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.
Lawren VandeVrede, Renaud La Joie, Sheena Horiki, Nidhi S Mundada, Mary Koestler
Acta Neuropathologica. 2025-02-13
Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers.
Lawren VandeVrede, Hanna Cho, Mark Sanderson-Cimino, Fattin Wekselman, Yann Cobigo
JAMA Neurology. 2025-02-10
1 citations
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2...
Kristy K L Coleman, Scott Berry, Jeffrey Cummings, Ging-Yuek R Hsiung, Robert Laforce
The Lancet. Neurology. 2025-02-01

Press Mentions

New Hope for Progressive Supranuclear Palsy with Innovative TrialSeptember 3rd, 2024
A Study Has Shown That a Blood Test Can Accurately Diagnose Alzheimer’s Disease in 90% of CasesJuly 28th, 2024
A Blood Test Accurately Diagnosed Alzheimer’s 90% of the Time, Study FindsJuly 28th, 2024
Join now to see all

Grant Support

Eye Movement Control In Normal Elderly And MCINational Institute On Aging2009–2012
Four Repeat Tauopathy Neuroimaging InitiativeNational Institute On Aging2010–2011
Ocular Motor Function And Decision-Making In FTLDNational Institute Of Neurological Disorders And Stroke2005–2009